CannEpil

CannEpil

Products

Information

CannEpil® is an Investigational Medicinal Product based on two APIs, high CBD and low THC, designed to be used for treatment of Drug-Resistant Epilepsy.​ We are in the process of registering a clinical trial at the FDA for a future NDA 505 (b)(2): A Phase-2b, Randomised, Double-Blind, Placebo-Controlled, Three-Arm Study to Evaluate the Efficacy and Safety of CannEpil® as an Adjuvant Therapy for Treatment of Drug-Resistant Epilepsy in Adults with Cerebral Palsy​
Argent BioPharma ltd7F78Argent BioPharma, an innovative drug discovery company listed on the London Stock Exchange, is enhancing its commitment to accessible medical treatments with advancements in poly pharmacology and nanotechnology. As a clinical-stage, revenue-generating biopharmaceutical company, we focus on addressing unmet medical needs through cutting-edge research and development. At Argent Biopharma, we provide comprehensive Contract Manufacturing Organization (CMO) services for non-sterile oral liquid dosage forms. With a GMP certified facility and fully automated production.

Join the event!